Access the full text.
Sign up today, get DeepDyve free for 14 days.
G Lip (2017)
10.1016/j.ahj.2017.07.010Am Heart J, 193
T. Gomes, M. Mamdani, A. Holbrook, Paterson Jm, C. Hellings, D. Juurlink (2013)
Rates of hemorrhage during warfarin therapy for atrial fibrillationCanadian Medical Association Journal, 185
G. Salanti, A. Ades, J. Ioannidis, J. Ioannidis, J. Ioannidis (2011)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.Journal of clinical epidemiology, 64 2
G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G. Raskob, J. Weitz (2013)
Oral apixaban for the treatment of acute venous thromboembolism.The New England journal of medicine, 369 9
S. Hohnloser, Z. Hijazi, L. Thomas, J. Alexander, J. Amerena, M. Hanna, M. Keltai, F. Lanas, R. Lopes, J. López-Sendón, C. Granger, L. Wallentin (2012)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.European heart journal, 33 22
M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, S. Goto, T. Izumi, Y. Koretsune, Mariko Kajikawa, Masaharu Kato, H. Ueda, K. Iwamoto, Masahiro Tajiri (2013)
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.Circulation journal : official journal of the Japanese Circulation Society, 77 3
E. Bohula, R. Giugliano, C. Ruff, J. Kuder, S. Murphy, E. Antman, E. Braunwald (2015)
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 TrialCirculation, 134
J. Carrero, M. Evans, K. Szummer, J. Spaak, L. Lindhagen, R. Edfors, P. Stenvinkel, S. Jacobson, T. Jernberg (2014)
Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.JAMA, 311 9
S. Genovesi, A. Santoro (2013)
Anticoagulants, renal failure and atrial fibrillationExpert Opinion on Drug Safety, 12
V. Wizemann, Lin Tong, S. Satayathum, A. Disney, T. Akiba, R. Fissell, P. Kerr, E. Young, B. Robinson (2010)
Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.Kidney international, 77 12
J. Levy, J. Douketis, J. Weitz (2018)
Reversal agents for non-vitamin K antagonist oral anticoagulantsNature Reviews Cardiology, 15
Z Hijazi (2014)
10.1161/CIRCULATIONAHA.113.003628Circulation, 130
A. Almutairi, Lili Zhou, W. Gellad, Jeannie Lee, M. Slack, Jennifer Martin, W. Lo‐Ciganic (2017)
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.Clinical therapeutics, 39 7
Junya Zhu, G. Alexander, S. Nazarian, Jodi Segal, A. Wu (2018)
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 38
Stefanie Sarratt, Ross Nesbit, Robert Moye (2017)
Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal DiseaseAnnals of Pharmacotherapy, 51
K. Fox, J. Piccini, D. Wojdyla, R. Becker, J. Halperin, C. Nessel, J. Paolini, G. Hankey, K. Mahaffey, M. Patel, D. Singer, R. Califf (2011)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.European heart journal, 32 19
(2014)
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. Circulation
Benjamin Miao, N. Sood, T. Bunz, C. Coleman (2020)
Rivaroxaban versus apixaban in non‐valvular atrial fibrillation patients with end‐stage renal disease or receiving dialysisEuropean Journal of Haematology, 104
M. Weir, V. Ashton, K. Moore, Shubham Shrivastava, E. Peterson, Eric Ammann (2020)
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.American heart journal, 223
H. Büller, H. Décousus, M. Grosso, M. Mercuri, S. Middeldorp, M. Prins, G. Raskob, S. Schellong, L. Schwocho, A. Segers, M. Shi, P. Verhamme, P. Wells (2013)
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.The New England journal of medicine, 369 15
D. Reed, Surabhi Palkimas, R. Hockman, Sumner Abraham, T. Le, Hillary Maitland (2018)
Safety and effectiveness of apixaban compared to warfarin in dialysis patientsResearch and Practice in Thrombosis and Haemostasis, 2
Kevin Chan, E. Edelman, J. Wenger, R. Thadhani, F. Maddux (2015)
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on HemodialysisCirculation, 131
Marco Proietti, P. Cheli, S. Basili, M. Mazurek, G. Lip (2017)
Balancing thromboembolic and bleeding risk with non‐vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta‐analysis on gender differencesPharmacological Research, 117
C. January, L. Wann, H. Calkins, Lin Chen, Joaquin Cigarroa, Joseph Cleveland, P. Ellinor, M. Ezekowitz, Michael Field, K. Furie, P. Heidenreich, Katherine Murray, Julie Shea, C. Tracy, C. Yancy (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart rhythm
JP Piccini (2013)
10.1161/CIRCULATIONAHA.112.107128Circulation, 127
C. Coleman, R. Kreutz, N. Sood, T. Bunz, D. Eriksson, A. Meinecke, W. Baker (2019)
Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.The American journal of medicine
S. Goldhaber, S. Schulman, H. Eriksson, M. Feuring, M. Fraessdorf, J. Kreuzer, E. Schüler, S. Schellong, A. Kakkar (2017)
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER IIThrombosis and Haemostasis, 117
N. Hawkins, P. Jhund, A. Pozzi, E. O’Meara, S. Solomon, C. Granger, S. Yusuf, M. Pfeffer, K. Swedberg, M. Petrie, S. Virani, J. McMurray (2016)
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustmentEuropean Journal of Heart Failure, 18
CT January (2019)
10.1016/j.jacc.2019.01.011JACC, 2019
I. White (2011)
Multivariate Random-effects Meta-regression: Updates to MvmetaThe Stata Journal, 11
(2015)
Impact of renal function on outcomes with 657 Safety and Efficacy of DOACs vs Warfarin in AF or VTE in Patients with Renal Impairment edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation
J. Higgins, D. Jackson, J. Barrett, G. Lu, A. Ades, Ian White (2012)
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies‡Research Synthesis Methods, 3
How well do the 56 , 183 atrial fibrillation patients enrolled in the contemporary novel oral anticoagulant ( NOAC ) trials reflect the real world ?
CB Granger (2011)
10.1056/NEJMoa1107039N Engl J Med, 35
John Stanifer, S. Pokorney, G. Chertow, S. Hohnloser, D. Wojdyla, S. Garonzik, W. Byon, Z. Hijazi, R. Lopes, J. Alexander, L. Wallentin, C. Granger (2020)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease, 141
Amy Schwinghammer, A. Isaacs, R. Benner, H. Freeman, Jacob O’Sullivan, S. Nisly (2017)
Continuous Infusion Ketorolac for Postoperative Analgesia Following Unilateral Total Knee ArthroplastyAnnals of Pharmacotherapy, 51
(2018)
Correction to: Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States.Circulation, 138 15
L. Stevens, J. Coresh, T. Greene, A. Levey (2006)
Assessing kidney function--measured and estimated glomerular filtration rate.The New England journal of medicine, 354 23
T. Ortel, I. Neumann, W. Ageno, R. Beyth, N. Clark, A. Cuker, B. Hutten, M. Jaff, Veena Manja, S. Schulman, Caitlin Thurston, S. Vedantham, P. Verhamme, D. Witt, Ivan Florez, A. Izcovich, R. Nieuwlaat, S. Ross, Holger Schünemann, W. Wiercioch, Yuan Zhang, Yuqing Zhang (2020)
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.Blood advances, 4 19
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
M. Prins, Anthonie Lensing, R. Bauersachs, B. Bellen, H. Bounameaux, T. Brighton, A. Cohen, B. Davidson, H. Décousus, G. Raskob, Scott Berkowitz, Philip Wells (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 11
A. Levey, J. Coresh, K. Bolton, B. Culleton, K. Harvey, T. Ikizler, C. Johnson, A. Kausz, P. Kimmel, J. Kusek, A. Levin, K. Minaker, R. Nelson, H. Rennke, M. Steffes, B. Witten, R. Hogg, S. Furth, K. Lemley, R. Portman, G. Schwartz, J. Lau, E. Balk, R. Perrone, T. Karim, Lara Rayan, Inas Al-Massry, P. Chew, B. Astor, De Vine, G. Eknoyan, N. Levin, S. Burrows‐Hudson, W. Keane, A. Kliger, D. Latos, D. Mapes, E. Oberley, K. Willis, G. Bailie, G. Becker, J. Burrowes, D. Churchill, A. Collins, W. Couser, D. Dezeeuw, A. Garber, T. Golper, F. Gotch, A. Gotto, J. Greer, R. Grimm, R. Hannah, J. Acosta, L. Hunsicker, M. Klag, S. Klahr, C. Lewis, E. Lowrie, A. Matas, S. McCulloch, Maureen Michael, J. Nally, J. Newmann, A. Nissenson, Keith Norris, W. Owen, T. Patel, G. Payne, R. Rivera-Mizzoni, David Smith, R. Star, T. Steinman, F. Valderrábano, J. Walls, J. Wauters, N. Wenger, J. Briggs (2002)
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.American journal of kidney diseases : the official journal of the National Kidney Foundation, 39 2 Suppl 1
S. Hohnloser, P. Steg, J. Oldgren, G. Nickenig, R. Kiss, Z. Ongen, J. Estrada, T. Ophuis, G. Lip, M. Nordaby, E. Kleine, J. Berg, Deepak Bhatt, C. Cannon (2018)
DOES RENAL FUNCTION INFLUENCE THE BENEFIT OF DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM RE-DUAL PCIJournal of the American College of Cardiology, 71
C. Granger, J. Alexander, J. McMurray, R. Lopes, E. Hylek, M. Hanna, H. Al-Khalidi, J. Ansell, D. Atar, Á. Avezum, M. Bahit, R. Diaz, J. Easton, J. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B. Gersh, S. Golitsyn, S. Goto, A. Hermosillo, S. Hohnloser, J. Horowitz, Puneet Mohan, P. Janský, B. Lewis, J. López-Sendón, P. Pais, A. Parkhomenko, F. Verheugt, Jun Zhu, L. Wallentin (2013)
Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trialEuropean Heart Journal, 34
BackgroundDue to the high risk of ischemic and arterial or venous bleeding events in atrial fibrillation (AF) or venous thromboembolism (VTE) patients with renal impairment (RI), selection of appropriate anticoagulant regimen is important. Therefore, we systematically reviewed and compared the safety and effects of oral anticoagulants in AF and VTE patients with RI.MethodsEligible articles were identified through a literature search in PubMed, Embase, ClinicalTrials.gov, and the Cochrane Library for studies published between January 2008 and November 2020. Network meta-analysis was conducted with STATA 14.0 to analyze the effects and safety of each drug with regard to different levels of renal function.Results15 studies including 82,931 patients (76,957 with AF and 5974 with VTE) were analyzed. Compared with those of warfarin, the risk ratios of effect and safety outcomes of apixaban were 0.70 (95% confidence interval [CI] 0.60–0.82) and 0.56 (95% CI 0.42–0.76) in AF patients and 0.33 (95% CI 0.19–0.59) and 0.95 (95% CI 0.68–1.34) in VTE patients. Apixaban had the first or second highest probability of being ranked first with respect to surface under the cumulative ranking curve (SUCRA) scores in the prevention of major bleeding events, while in the prevention of ischemic events, rivaroxaban showed a higher SUCRA score (0.78–0.92) in mild RI patients and dabigatran showed a higher SUCRA value (0.90–0.99) in moderate RI patients.Conclusions and RelevanceIn the systematic review and meta-analysis, for AF or VTE patients with RI, direct oral anticoagulants performed comparably to or better than warfarin with regard to safety and effects. The network meta-analysis indicated that for patients with mild RI, apixaban might be safer for patients with a lower risk of ischemic events, while rivaroxaban might be suitable for patients with a lower risk of bleeding events. For patients with moderate RI, apixaban could reduce the risk of ischemic events without increasing the risk of bleeding events. For AF patients with severe RI, apixaban, rivaroxaban, and warfarin showed a similar effect. These results might provide suggestions for clinical arterial and venous thrombosis prevention.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Nov 1, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.